Dr. Li Liang, Associate Professor, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences


Mail: Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Xueyuan Avenue 1068, Nanshan District, Shenzhen, Guangdong, China

Research Areas

Assoc/Prof Li Liang’s research focuses on respiratory infection and host responses using primary cell culture, airway epithelial organoids reconstructed from clinical samples, animal models and multi-center clinical sample analysis. His team develops innovative diagnostic and therapeutic strategies through combining basic and clinical research. He published papers in journals such as mBio, Cell Reports, Antiviral Research, ACS Applied Materials & Interfaces, BMC Genomics, Oncogene and Cell Death and Disease. His research outcomes got global interest in news reports for various countries, patented in US and EU, and received collaborations from pharmaceutical companies and investors. He collaborates with hospitals in China and overseas, including Nagasaki University Hospital (Japan), Centre Hospitalier Universitaire de Dijon (France), and National University Hospital (Singapore), for research that further promotes the potential clinical application of the findings in disease pathogenesis. The combination of basic and clinical research enables the bench to bed translation of the research findings of his team.  


PhD, 2016, National University of Singapore


Work Experience

Research Fellow, 2016-02~2018-07, Nanyang Technological University



The Time Sequences of Oral and Fecal Viral Shedding of Coronavirus Disease 2019 (COVID-19) Patients, Gastroenterology, 2020

Serum Creatinine as a Potential Biomarker for the Diagnosis of Tuberculous Pleural Effusion, the American Journal of the Medical Sciences, 2020

Antibody treatment against angiopoietin-like 4 reduces pulmonary edema and injury in secondary pneumococcal pneumonia, mBio, 2019

Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells, Frontiers in Oncology, 2018

Angiopoietin-like 4 increases pulmonary tissue leakiness and damage during influenza pneumonia, Cell Reports, 2015

Angiopoietin-related protein 4 (cANGPTL4) as a diagnostic biomarker for acute lung damage, Patented: US , 2018, (US10160803B2), EU (2019, EP2948470B1)